Related Content
The Fortitude sirolimus-eluting bioresorbable stent.
News | Stents Bioresorbable| November 07, 2016
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 in Washington, D.C...
Fantom image courtesy of REVA Medical Inc.
News | June 05, 2015
REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom...
Image courtesy of Reva Medical Inc.
News | February 12, 2015
A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University...
Image courtesy of Reva
News | December 31, 2014
Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold.
Abbott has spearheaded bioresorbable stent technology with the development with its BVS. By far the BVS has the most clinical experience, with more than 13,000 patients around the world having been treated with the device.
Feature | Stents Bioresorbable| September 03, 2014 | Dave Fornell
A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and...
News | April 02, 2013
Reva Medical Inc. announced that it has initiated patient enrollment with its ReZolve2 bioresorbable sirolimus-eluting...
News | July 16, 2012
July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting...
